No Data
Absci and Twist Bioscience Collaborate to Design Novel Antibody Using Generative AI
Absci to Report Business Updates and Third Quarter 2024 Financial and Operating Results on November 12, 2024
Absci Started by Guggenheim at Buy on Pioneer Status in AI Drug Design
Absci Initiated at Buy by Guggenheim
Guggenheim Initiates Absci Corp(ABSI.US) With Buy Rating, Announces Target Price $10
Is Absci (NASDAQ:ABSI) Using Debt In A Risky Way?